Month: September 2026

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Western Pacific Trust Company (“WPTC”) is pleased to announce that its Board of Directors has declared its fourth consecutive annual dividend on common shares. The dividend reflects WPTC’s continued financial strength and the Board’s confidence in the Company’s long-term outlook.

The declaration follows another year of solid performance and continued progress across WPTC’s core business. Despite ongoing economic and market uncertainty, the Company has remained focused on providing responsive, specialized trust services to its clients while maintaining a strong and stable financial position.

“We are pleased to declare our fourth consecutive annual dividend on common shares,” said Alison Alfer, President & CEO. “The dividend reflects the strength and stability of WPTC’s business and our confidence in the Company’s long-term strategy. We remain focused on disciplined growth, maintaining a strong financial foundation, and delivering sustainable value to our shareholders.”

A dividend of $0.005 per common share will be payable on October 16, 2026, to shareholders of record as of the close of business on October 1, 2026.

Western Pacific Trust Company designates the full amount of this taxable dividend as an “eligible dividend” for purposes of the Income Tax Act (Canada), as amended from time to time. Shareholders are encouraged to consult their tax advisors regarding the implications of this designation.

For more information about Western Pacific Trust Company, please visit www.westernpacifictrust.com.

About Western Pacific Trust Company
WPTC is a licensed trust company authorized to conduct non-deposit taking trust business in British Columbia, Alberta, and Saskatchewan.

Media Contact:
Alison Alfer, President & CEO
Phone: (604) 683-0455
Email: aalfer@westernpacifictrust.com

LOS ANGELES, Sept. 10, 2026 (GLOBE NEWSWIRE) — Lineage, Inc. (NASDAQ: LINE) today filed a civil lawsuit in Los Angeles Superior Court against Altus Power, Inc., a commercial solar operator, and its contractor Pearce Services LLC, a subsidiary of CBRE Group, alleging that their negligence caused the June 17, 2026, fire that destroyed Lineage’s 500,000 square-foot cold storage facility in the Boyle Heights neighborhood in Los Angeles.

Key points from the suit:

• Altus and Pearce’s negligence started the fire. They abandoned Lineage to clean up the site on their own and ignored the Boyle Heights community. This was a solar fire, not a warehouse fire.
• Altus was and is the owner of the solar array, and this was not Altus’ first fire at the facility. In August 2024, the same solar array sparked a smaller fire on the facility’s roof. Following that incident, Lineage called for enhanced safety measures before the array could be re-energized, and Altus retained Pearce to reconfigure the array. By May 2026, more than 200 connector failures had been identified across the array, including in the section where the June fire would begin.
• Altus and Pearce disregarded Lineage’s written safety directives and re-energized a defective rooftop solar array before required safety checks were completed – days before the fire.
• On June 11, 2026, Lineage notified Altus in writing that the system should not be re-energized until critical safety tests were completed. Altus and Pearce deliberately ignored those instructions. Beginning on June 5 and continuing through June 17, the array was energized without completing the required testing and before all work on the array had been completed. The fire ignited on June 17 while Pearce personnel were working on the energized system.
• When the community needed direct assistance and the site cleaned up, Altus and Pearce did nothing. Lineage has a longstanding track record of operating with the highest degree of integrity backed by the Company’s commitments to the communities and customers it serves. Since the fire began, Lineage has provided community support including direct financial assistance, relocation, air conditioners, air purifiers and grocery cards. With the cleanup completed, Lineage’s commitment to the community of Boyle Heights continues, and the Company remains dedicated to ongoing and transparent communication with neighbors and local community organizations to understand ongoing needs.

“This lawsuit is about Altus and Pearce starting this fire and then being nowhere to be found when the community needed help,” said Greg Lehmkuhl, President & CEO of Lineage. “From the moment it started, Lineage stood alone in supporting remediation and cleanup efforts for a neighborhood impacted through absolutely no fault of our own. The record is clear: this was a solar fire. Cold storage is not a risk to communities – it is an essential service that lowers food costs, expands food access and creates jobs. We are grateful to each and every worker who contributed over 210,000 hours to complete this unprecedented and complex cleanup in record time. We want to thank the community of Boyle Heights and East LA for their patience during this process. With the cleanup completed, now is the right time to pursue accountability and recover the substantial losses we incurred as a result of Altus’s and Pearce’s negligence.”

For more information, please visit: https://www.onelineage.com/boyle-heights-fire-response.

About Lineage, Inc.
Lineage, Inc. (NASDAQ: LINE) partners with food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at onelineage.com and join us
on LinkedIn, Facebook, Instagram, and X.

Forward-Looking Statements
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage’s performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.

While the forward-looking statements are considered reasonable by the Company, they are subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond the control of the Company and cannot be predicted with accuracy and may not be realized. There can be no assurance that the forward-looking statements can or will be attained or maintained. Actual operating results may vary materially from the forward-looking statements included in this Press Release.

Media Contact
Megan Klein
VP, Global Marketing & Communications
pr@onelineage.com

ANNOUNCEMENT NO. 313
10 September 2026

Annual Report 2025/26 (1 July 2025 – 30 June 2026)

Positioning ChemoMetec for future growth

Despite changes and uncertainty affecting ChemoMetec’s markets, revenue grew by 3% to DKK 511.1 million in 2025/26 whilst EBITDA grew from DKK 258.0 million to DKK 281.3 million. The growth was driven by increased sales of new instruments and services, with sales of XcytoMatic instruments rising from DKK 27.7 million to DKK 61.8 million. Towards the end of the financial year, we noted a further increase in demand for the more recent products, in part due to the phasing out of older instruments.

“We are in the midst of a period of significant change in our markets – in part as a result of our customers’ strong focus on automation. Over the past year, we have therefore taken a number of important steps to place ChemoMetec in a position to be able to leverage these new opportunities. The launch of our XcytoMatic products, including the replacement of the NC-200 with the NC-203, and increased collaboration with other leading players in our field give us a solid foundation for driving growth in the coming years.

In many cases, ChemoMetec is chosen as supplier of cell counting equipment, and we also see a number of customers purchasing a combination of our products, as the instruments are suitable for different functions within their respective organisations. This is in part attributable to the fact that, with our new XcytoMatic platform, we are one of the only suppliers whose products can be integrated into larger automation solutions, and that we also supply state-of-the-art semi-automated cell counters for smaller integrated setups. We thus supply equipment that meets our customers’ wide-ranging needs and varying degrees of automation.

Over the past few years, we have worked on strengthening our position in the bioprocessing sector, and our XcytoMatic products and our customers’ focus on automation have opened up new opportunities for ChemoMetec. To enable us to offer our customers the overall automation solutions they request, we devoted considerable resources in the past year to establishing collaborations with partners in the industry. In particular, we are looking to establish partnerships with suppliers providing solutions to bioprocessing customers worldwide, and we are very confident that such partnerships will make a contribution to our growth in the coming years and help us build a stronger market position in the bioprocessing sector.

In the coming year, our primary focus will be on further stepping up the marketing of our latest XcytoMatic products, for example through partnerships, continuing the development of the XcytoMatic platform, including the XcytoMatic Octopus software solution, establishing new partnerships and further developing existing ones, as well as on continuing to strengthen our organisation. Another major undertaking in the coming years will be replacing the NC-200 with the NC-203, and the work involved in driving increased sales through the new partnerships and jointly developing integration solutions will also require significant and focused efforts,” says Martin Helbo Behrens, CEO.

Financial results

• ChemoMetec’s revenue grew by 3% to DKK 511.1 million in 2025/26. At constant exchange rates, revenue grew by 7%. 
• ChemoMetec’s revenue is distributed with 54% in the USA/Canada, 36% in Europe and 10% in the rest of the world.
• Revenue in the USA/Canada region was down by 6% measured in Danish kroner, whereas it grew by 1% measured at constant exchange rates. In Europe, revenue grew by 14%, while revenue in the rest of the world grew by 21%.
• Sales of instruments and services increased by 13% and 4%, respectively, in 2025/26 while sales of consumables declined by 4%.
• EBITDA grew from DKK 258.0 million to DKK 281.3 million. The improvement was primarily attributable to the revenue growth and reduced staff costs.
• The EBITDA margin grew to 55%, against 52% in 2024/25.
• Profit for the year amounted to DKK 201.8 million, against DKK 174.7 million in 2024/25.
• Revenue and EBITDA for the year were both within the most recent guidance ranges announced on 4 May 2026 of DKK 505-525 million and DKK 275-290 million, respectively.
• Despite ChemoMetec’s strong financial position, the Board of Directors will propose to the annual general meeting that no dividend be distributed for the 2025/26 financial year. The proposal should be seen in the context of the ongoing share buy-back programme.

Guidance

• For 2026/27, ChemoMetec expects revenue in the range of DKK 545-575 million and EBITDA in the range of DKK 300-315 million.

Conference call

The Company will host a conference call on Friday, 11 September at 3:00 p.m., at which Martin Helbo Behrens, CEO, and Phillip Massie Price, CFO, will present the annual report for 2025/26 and answer any questions.

The conference call will be conducted in English.

To attend, please click this link.

Additional information

Martin Helbo Behrens, CEO
Tel.: (+45) 81 10 06 80 

Phillip Massie Price, CFO
Tel.: (+45) 81 10 06 80 

Attachments to this announcement

• Annual Report 2025/26 (Danish)
• Annual Report 2025/26 (English)

The annual report may also be downloaded from ChemoMetec’s website www.chemometec.com

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.

Attachment

• Annual Report 2025-26 (English)